OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc.Apr 22 2014

OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50^th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois. Additional details will be made available on or after May 14, 2014, via the ASCO webpage: http://www.asco.org

"It is an honor to be selected to present in a Poster Highlights Session at this year's conference," said Punit Dhillon, President and CEO of OncoSec Medical. "We salute ASCO's efforts to advance oncology research and look forward to sharing data from our Phase 2 melanoma study with conference attendees and participants."

Lead author, Dr. Adil Daud, will present an abstract titled, "Systemic anti-tumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma" (ASCO Abstract #9025), which highlights unreleased data from the company's Phase 2 study investigating the use of ImmunoPulse in patients with metastatic melanoma. The abstract will be part of the Poster Highlights Session: Melanoma and Skin Cancers, taking place June 2, 2014. For more information, please refer to the ASCO iPlanner: https://iplanner.asco.org/AM2014

Said Robert Pierce, M.D., Chief Medical Officer, "We are excited by the opportunity to present data from our Phase 2 study, which is nearing completion. Our presentation will be one of those highlighting the therapeutic potential of intralesional therapy and the power of modulating the immune system in the treatment of cancer."

ASCO 2014 will bring together over 25,000 oncology professionals from a wide range of specialties to explore this year's theme - "Science and Society". Attendees will have access to cutting-edge scientific presentations and comprehensive educational content that reflect ASCO's dedication to providing the highest-quality resources in education, policy, the pioneering of clinical research, and the advancement of care for patients with cancer.